Valeant Pharmaceuticals International Inactive 10-Q2002 Q3 Quarterly report

Filed: 14 Nov 02, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. sophomore Avg

New words: abbreviated, accrual, add, Adjunct, admit, advisory, aforementioned, alma, Arcadian, area, Bailey, Barker, Bary, Bedoyecta, begun, Bolstering, bond, broaden, catalog, chain, Chancery, classification, Comany, committee, Coraceten, Corning, corrective, Covance, Coventry, criteria, Czech, damage, death, declaratory, decommissioning, defined, deny, designed, device, disability, disclosure, divest, divesting, Dr, educational, emphasize, exert, exit, expiration, explore, Exploring, extend, factory, fill, fit, flood, founder, Geneva, greater, Hepavair, Human, imposition, infringe, infringement, invalid, investor, Italy, Jefferson, joint, Jr, Kim, Kugelman, Lamon, Larry, laser, mater, maturity, McCoy, meantime, Medicine, modifing, network, Norman, oversight, ownership, Pacific, Pan, parent, patent, percent, permanent, Pharmacology, physician, pipeline, Poulenc, Premier, processed, Professor, Pursuing, rationalize, readily, Refocusing, reimburse, reimbursement, reinforce, remediation, repositioning, retire, Rhone, Roderick, Rorer, School, scientific, SciPharma, serve, served, shipped, significantly, Solcoseryl, specialty, stipulated, stipulation, sued, summarized, Taylor, telephonic, TEMODAR, Teva, therapeutic, Timothy, Tyson, understand, unenforceable, University, unreasonably, unrelated, USA, vacancy, venture, version, Vice, voluntarily

Removed: attributable, combined, comprised, consent, consummated, evaluating, finance, fund, geographical, preliminary, publicly, schedule, separate, stream, sufficient, traded, transition, ultimately

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Valeant Pharmaceuticals International similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 15.1

REVIEW REPORT OF INDEPENDENT ACCOUNTANTS

The Board of Directors and Stockholders of

ICN Pharmaceuticals, Inc.

We have reviewed the accompanying consolidated condensed balance sheet of ICN Pharmaceuticals, Inc. and its subsidiaries as of September 30, 2002, the related consolidated condensed statements of income and comprehensive income for each of the three-month and nine-month periods ended September 30, 2002 and 2001 and the consolidated condensed statements of cash flows for the nine months ended September 30, 2002 and 2001. These consolidated condensed financial statements are the responsibility of the Company’s management.

We conducted our review in accordance with standards established by the American Institute of Certified Public Accountants. A review of interim financial information consists principally of applying analytical procedures to financial data and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with generally accepted auditing standards, the objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly, we do not express such an opinion.

Based on our review, we are not aware of any material modifications that should be made to the accompanying consolidated condensed interim financial statements for them to be in conformity with accounting principles generally accepted in the United States of America.

We previously audited in accordance with auditing standards generally accepted in the United States of America, the consolidated balance sheet as of December 31, 2001, and the related consolidated statements of income, stockholders’ equity and cash flows for the year then ended (not presented herein), and in our report dated February 27, 2002, we expressed an unqualified opinion on those consolidated financial statements. In our opinion, the information set forth in the consolidated condensed balance sheet as of December 31, 2001, is fairly stated in all material respects in relation to the consolidated balance sheet from which it has been derived.

/s/ PricewaterhouseCoopers LLP

PricewaterhouseCoopers LLP

Los Angeles, California

November 6, 2002

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.